Sort   by:  
 Page size 
TranscriptomicsA stroma-related gene signature predicts sensitivity to epirubicin-containing neoadjuvant chemotherapy in breast cancer.
The goal of the study was to identify a gene expression signature capable of predicting a pathological complete response following neoadjuvant anthracycline-based chemotherapy of breast cancer. The samples were taken from the FEC arm (5-fluorouracil, epirubicin, cyclophosphamide) of the EORTC 10994 ...
ORGANISM(S): Homo sapiens 
2008-12-19 | E-GEOD-4779 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human ovarian cancer cell lines grown as multicellular spheroids and treated with three chemotherapy drugs
Gene expression profiling of ovarian cancer spheroids upon treatment with three chemotherapy drugs
ORGANISM(S): Homo sapiens 
2008-05-06 | E-MEXP-1319 | biostudies-arrayexpress
ProteomicsLactylome and proteomics analyses of bladder cancer
Lactylome and proteomics analyses in bladder cancer cells treated with EPI
ORGANISM(S): Homo sapiens (Human) 
2025-06-10 | PXD062720 | Pride
Epi chemotherapy Bladder cancer 
TranscriptomicsOligonucleotide Array CGH Profiles of Breast Cancer Patients Treated with High Dose or Conventional Chemotherapy
DNA copy number profiles can identify patients with a defect in BRCA1 or BRCA2. We previously showed that patients with a BRCA1 like profile benefit from intensified alkylating chemotherapy (IA, 4 cycles 5-fluorouracyl (5FU), epirubicin, cyclophosphamide (C) + 1 cycle carboplatin, thiotepa and cycl...
ORGANISM(S): Homo sapiens 
2014-12-22 | E-GEOD-50407 | biostudies-arrayexpress
TranscriptomicsNCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules
This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA...
ORGANISM(S): Homo sapiens 
2015-11-11 | E-GEOD-66999 | biostudies-arrayexpress
TranscriptomicsGenomic Multivariate Predictors of Response to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance
Purpose: Despite advances in radical surgery and chemotherapy delivery, ovarian cancer is the most lethal gynecologic malignancy. Most of these patients are treated with platinum-based chemotherapies, but there is no biomarker model to guide their responses to these therapeutic agents. We have d...
ORGANISM(S): Homo sapiens 
2012-08-21 | E-GEOD-30161 | biostudies-arrayexpress
TranscriptomicsResponse to Neoadjuvant Chemotherapy in Triple Negative Breast tumors.
In a cohort study of 7 women with primary invasive breast cancer, we obtained a tumor specimen before (biopsy) and after (tumorectomy) 4 cycles of NAC with epirubicine and cyclophosphamide, followed by 4 cycles of taxanes. Total RNA was extracted from tumor specimens and the whole transcriptome was ...
ORGANISM(S): Homo sapiens 
2016-03-24 | E-GEOD-43816 | biostudies-arrayexpress
TranscriptomicsExpression data from breast cancer FNA biopsies from patients (US samples)
This is Phase II Trial of 4courses of 5-fluorouracil, doxorubicin and cyclophosphamide follwed by 4 additional courses of weekly docetaxel and capecitabine administered as Preoperative Therapy for Patients with Locally Advanced Breast Cancer, Stages II and III by US oncology (PROTOCOL 02-103) We per...
ORGANISM(S): Homo sapiens 
2011-02-07 | E-GEOD-23988 | biostudies-arrayexpress
TranscriptomicsExpression data from breast cancer FNA biopsies from patients
We assess if distinct biological processes might be associated with chemotherapy sensitivity in the different clinical subsets of breast cancers. We performed gene set analysis (GSA) using functionally annotated gene sets corresponding to almost all known biological processes in ER-positive/HER2nega...
ORGANISM(S): Homo sapiens 
2010-12-31 | E-GEOD-22093 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of breast cancer samples to predict response to anthracycline/taxane chemotherapy .
EORTC 10994 phase III breast cancer clinical trial comparing FEC (5-fluorouracil, cyclophosphamide, epirubicin) with ET (epirubicin, docetaxel). 161 needle biopsies of locally advanced or large operable breast tumours were hybridised to Affymetrix X3P chips. The array data from the ER negative ...
ORGANISM(S): Homo sapiens 
2008-06-15 | E-GEOD-6861 | biostudies-arrayexpress
Sort   by:  
 Page size